Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 06 2019
Historique:
received: 11 07 2018
revised: 18 10 2018
accepted: 07 11 2018
pubmed: 30 11 2018
medline: 4 9 2019
entrez: 29 11 2018
Statut: ppublish

Résumé

Primary liver cancer (PLC) ranks among the most lethal solid cancers worldwide due to lack of effective biomarkers for early detection and limited treatment options in advanced stages. Development of primary culture models that closely recapitulate phenotypic and molecular diversities of PLC is urgently needed to improve the patient outcome. Long-term cultures of 7 primary liver cancer cell lines of hepatocellular and cholangiocellular origin were established using defined culture conditions. Morphological and histological characteristics of obtained cell lines and xenograft tumors were analyzed and compared to original tumors. Time course analyses of transcriptomic and genomic changes were performed using next-generation sequencing (NGS). Key oncogenic alterations were identified by targeted NGS and cell lines carrying potentially actionable mutations were treated with corresponding specific inhibitors. PDCL fully resembled morphological features of the primary cancers in vitro and in vivo over extended period in culture. Genomic alterations as well as transcriptome profiles showed high similarity with primary tumors and remained stable during long-term culturing. Targeted-NGS confirmed that key oncogenic mutations such as TP53, KRAS, CTNNB1 as well as actionable mutations (e.g. MET, cKIT, KDR) were highly conserved in PDCL and amenable for individualized therapeutic approaches. Integrative genomic and transcriptomic approaches further demonstrated that PDCL more closely resemble molecular and prognostic features of PLC than established cell lines and are valuable tool for direct target evaluation. Our integrative analysis demonstrates that PDCL represents refined model for discovery of relevant molecular subgroups and exploration of precision medicine approaches for the treatment of this deadly disease.

Identifiants

pubmed: 30485423
doi: 10.1002/ijc.32026
doi:

Substances chimiques

Antineoplastic Agents 0
Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2782-2794

Informations de copyright

© 2018 UICC.

Auteurs

Darko Castven (D)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Diana Becker (D)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Carolin Czauderna (C)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Diana Wilhelm (D)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Jesper B Andersen (JB)

Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.

Susanne Strand (S)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Monika Hartmann (M)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Stefanie Heilmann-Heimbach (S)

Institute of Human Genetics, University of Bonn School of Medicine & University Hospital of Bonn Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany.
Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany.

Wilfried Roth (W)

Institute of Pathology, Johannes Gutenberg University, Mainz, Germany.

Nils Hartmann (N)

Institute of Pathology, Johannes Gutenberg University, Mainz, Germany.

Beate K Straub (BK)

Institute of Pathology, Johannes Gutenberg University, Mainz, Germany.

Friederike L Mahn (FL)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Sophia Franck (S)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Sharon Pereira (S)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Anna Haupts (A)

Institute of Pathology, Johannes Gutenberg University, Mainz, Germany.

Arndt Vogel (A)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Marcus A Wörns (MA)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Arndt Weinmann (A)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Stefan Heinrich (S)

Department of Surgery, Johannes Gutenberg University, Mainz, Germany.

Hauke Lang (H)

Department of Surgery, Johannes Gutenberg University, Mainz, Germany.

Snorri S Thorgeirsson (SS)

Laboratory of Human Carcinogenesis (LHC), Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

Peter R Galle (PR)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Jens U Marquardt (JU)

Department of Medicine I, Lichtenberg Research Group, Johannes Gutenberg University, Mainz, Germany.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH